Celera Group (CRA)
()
 
 

Overview

Celera is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets.


Contact Information

301 Merritt 7
Norwalk, CT 06851

tel: 203-840-2000
fax:
http://www.celera.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NYSE
Industry: Scientific & Technical Instruments
Market Cap: $984.5M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.